US4526988A
(en)
*
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
DE3587500T2
(de)
*
|
1984-12-04 |
1993-12-16 |
Lilly Co Eli |
Tumorbehandlung bei Säugetieren.
|
ZA859008B
(en)
*
|
1984-12-04 |
1987-07-29 |
Lilly Co Eli |
The treatment of tumors in mammals
|
CA1295998C
(en)
*
|
1985-07-29 |
1992-02-18 |
Sai P. Sunkara |
Nucleosides and their use as antineoplastic agents
|
US4681873A
(en)
*
|
1985-07-29 |
1987-07-21 |
Warner-Lambert Company |
4-amino-3-halo-2-pyridinone nucleoside and nucleotide compounds
|
PT86377B
(pt)
*
|
1986-12-24 |
1990-11-20 |
Lilly Co Eli |
Processo para a preparacao de conjugados de imunoglobulinas com um difluoronucleosideo acilado
|
US4814438A
(en)
*
|
1986-12-24 |
1989-03-21 |
Eli Lilly And Company |
Immunoglobulin conjugates of 2',2'-difluronucleosides
|
US4994558A
(en)
*
|
1986-12-24 |
1991-02-19 |
Eli Lilly And Company |
Immunoglobulin conjugates
|
EP0277599A3
(en)
*
|
1987-01-30 |
1990-05-09 |
Asahi Glass Company Ltd. |
Fluorine containing cyclopentane derivatives and processes for their production
|
CA1340645C
(en)
*
|
1987-04-17 |
1999-07-13 |
Victor E. Marquez |
Acid stable dideoxynucleosides active against the cytopathic effects of human immunodeficiency virus
|
US4965374A
(en)
*
|
1987-08-28 |
1990-10-23 |
Eli Lilly And Company |
Process for and intermediates of 2',2'-difluoronucleosides
|
ES2131152T3
(es)
*
|
1987-08-28 |
1999-07-16 |
Lilly Co Eli |
Procedimiento para aislar selectivamente beta-2'-desoxi-2',2'-difluorocitidina o sus sales.
|
US5223608A
(en)
*
|
1987-08-28 |
1993-06-29 |
Eli Lilly And Company |
Process for and intermediates of 2',2'-difluoronucleosides
|
US4914028A
(en)
*
|
1988-02-10 |
1990-04-03 |
Eli Lilly And Company |
Method of preparing beta-2',2'-difluoronucleosides
|
US5644043A
(en)
*
|
1988-02-16 |
1997-07-01 |
Eli Lilly And Company |
2',3'-dideoxy-2',2'-difluoronucleosides and intermediates
|
ES2075040T3
(es)
*
|
1988-02-16 |
1995-10-01 |
Lilly Co Eli |
2',3'-dideoxi-2',2'-difluoronucleosidos.
|
US4983724A
(en)
*
|
1988-02-16 |
1991-01-08 |
Eli Lilly And Company |
Inversion of 2,2-difluororibose to a 2,2-difluoroxylose and intermediates therefor
|
EP0364559B1
(en)
*
|
1988-03-16 |
1995-09-20 |
The Scripps Research Institute |
Substituted adenine derivatives useful as therapeutic agents
|
US5057301A
(en)
*
|
1988-04-06 |
1991-10-15 |
Neorx Corporation |
Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
|
JPH0232093A
(ja)
*
|
1988-06-08 |
1990-02-01 |
Merrell Dow Pharmaceut Inc |
抗レトロウィルスジフルオロ化ヌクレオシド類
|
US4987224A
(en)
*
|
1988-08-02 |
1991-01-22 |
University Of Georgia Research Foundation, Inc. |
Method of preparation of 2',3'-dideoxynucleosides
|
US5157114A
(en)
*
|
1988-08-19 |
1992-10-20 |
Burroughs Wellcome Co. |
2',3'-dideoxy-3'-fluoro-5-ethyngluridine
|
US4954623A
(en)
*
|
1989-03-20 |
1990-09-04 |
Eli Lilly And Company |
Recovery of difluoro sugar
|
CA2012129A1
(en)
*
|
1989-03-20 |
1990-09-20 |
Ramakrishnan Nagarajan |
Recovery of difluoro sugar
|
US5426183A
(en)
*
|
1992-06-22 |
1995-06-20 |
Eli Lilly And Company |
Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
US5256798A
(en)
*
|
1992-06-22 |
1993-10-26 |
Eli Lilly And Company |
Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
|
US5821357A
(en)
*
|
1992-06-22 |
1998-10-13 |
Eli Lilly And Company |
Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
|
US5252756A
(en)
*
|
1992-06-22 |
1993-10-12 |
Eli Lilly And Company |
Process for preparing beta-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl-arylsulfonates
|
JP3291071B2
(ja)
*
|
1992-06-22 |
2002-06-10 |
イーライ・リリー・アンド・カンパニー |
アルファ−アノマーに富む1−ハロ−2−デオキシ−2,2−ジフルオロ−d−リボフラノシル誘導体の製造方法
|
US5256797A
(en)
*
|
1992-06-22 |
1993-10-26 |
Eli Lilly And Company |
Process for separating 2-deoxy-2,2-difluoro-D-ribofuranosyl alkylsulfonate anomers
|
US5594124A
(en)
*
|
1992-06-22 |
1997-01-14 |
Eli Lilly And Company |
Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
|
CZ123493A3
(en)
*
|
1992-06-22 |
1994-02-16 |
Lilly Co Eli |
Stereoselective anionic glycosylation process
|
US5606048A
(en)
*
|
1992-06-22 |
1997-02-25 |
Eli Lilly And Company |
Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
US5401861A
(en)
*
|
1992-06-22 |
1995-03-28 |
Eli Lilly And Company |
Low temperature process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
|
US5371210A
(en)
*
|
1992-06-22 |
1994-12-06 |
Eli Lilly And Company |
Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
US5401838A
(en)
*
|
1992-06-22 |
1995-03-28 |
Eli Lilly And Company |
Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
YU43193A
(sh)
*
|
1992-06-22 |
1997-01-08 |
Eli Lilly And Company |
2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
|
US5424416A
(en)
*
|
1993-08-25 |
1995-06-13 |
Eli Lilly And Company |
Process for preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonates and their use in preparation of 2',2'-difluoro-2'-deoxy nucleosides
|
US5480992A
(en)
*
|
1993-09-16 |
1996-01-02 |
Eli Lilly And Company |
Anomeric fluororibosyl amines
|
US5428176A
(en)
*
|
1994-04-14 |
1995-06-27 |
Eli Lilly And Company |
Process for preparing 2,2-difluoroketene silyl O,S-acetals and α,α-difluoro-β-silyloxy-1,3-dioxolane-4-propanoic acid O,S-esters
|
US5637688A
(en)
*
|
1994-12-13 |
1997-06-10 |
Eli Lilly And Company |
Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
|
US5521294A
(en)
*
|
1995-01-18 |
1996-05-28 |
Eli Lilly And Company |
2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
|
US5559222A
(en)
*
|
1995-02-03 |
1996-09-24 |
Eli Lilly And Company |
Preparation of 1-(2'-deoxy-2',2'-difluoro-D-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
|
US5633367A
(en)
*
|
1995-03-24 |
1997-05-27 |
Eli Lilly And Company |
Process for the preparation of a 2-substituted 3,3-difluorofuran
|
CA2171518A1
(en)
*
|
1995-03-24 |
1996-09-25 |
Douglas Patton Kjell |
Process for the preparation of 2,2'-anhydro- and 2' -keto-1-(3', 5'-di-o-protected-.beta.-d-arabinofuranosyl) nucleosides
|
US6001994A
(en)
*
|
1995-12-13 |
1999-12-14 |
Eli Lilly And Company |
Process for making gemcitabine hydrochloride
|
US5756775A
(en)
*
|
1995-12-13 |
1998-05-26 |
Eli Lilly And Company |
Process to make α,α-difluoro-β-hydroxyl thiol esters
|
WO1997021719A1
(en)
|
1995-12-13 |
1997-06-19 |
Eli Lilly And Company |
α, α-DIFLUORO-β-HYDROXY THIOL ESTERS AND THEIR SYNTHESIS
|
US5808020A
(en)
*
|
1996-08-12 |
1998-09-15 |
Associated Universities, Inc. |
Optical reaction cell and light source for 18F! fluoride radiotracer synthesis
|
US6013790A
(en)
*
|
1996-09-25 |
2000-01-11 |
Board Of Regents University Of Nebraska-Lincoln |
Heavily fluorinated sugar analogs
|
CA2284263A1
(en)
*
|
1997-03-24 |
1998-10-01 |
Eli Lilly And Company |
Difluoronucleoside phosphonic acids and derivatives thereof
|
JP2002504558A
(ja)
|
1998-02-25 |
2002-02-12 |
エモリー ユニバーシテイ |
2’−フルオロヌクレオシド
|
TW466112B
(en)
*
|
1998-04-14 |
2001-12-01 |
Lilly Co Eli |
Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
|
US6326507B1
(en)
|
1998-06-19 |
2001-12-04 |
Trustees Of Dartmouth College |
Therapeutic compounds and methods of use
|
US20030008841A1
(en)
*
|
2000-08-30 |
2003-01-09 |
Rene Devos |
Anti-HCV nucleoside derivatives
|
NZ525324A
(en)
*
|
2000-10-20 |
2005-03-24 |
Eisai Co Ltd |
Nitrogenous aromatic ring compounds
|
US7435755B2
(en)
*
|
2000-11-28 |
2008-10-14 |
The Trustees Of Dartmouth College |
CDDO-compounds and combination therapies thereof
|
US8481712B2
(en)
|
2001-01-22 |
2013-07-09 |
Merck Sharp & Dohme Corp. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
AU2002365256A1
(en)
*
|
2001-10-25 |
2003-07-30 |
Eli Lilly And Company |
Gemcitabine in the treatment of smallpox
|
CA2472581C
(en)
*
|
2002-01-15 |
2012-06-26 |
Trustees Of Dartmouth College |
Tricyclic-bis-enone derivatives and methods of use thereof
|
CA2476279A1
(en)
*
|
2002-02-14 |
2003-08-21 |
Lieven J. Stuyver |
Modified fluorinated nucleoside analogues
|
US7994159B2
(en)
*
|
2003-03-10 |
2011-08-09 |
Eisai R&D Management Co., Ltd. |
c-Kit kinase inhibitor
|
AU2003239510A1
(en)
*
|
2003-05-20 |
2005-01-21 |
Aronex Pharmaceuticals, Inc. |
Combination chemotherapy comprising gemcitabine and a liposomal platinum complex
|
US20080026044A1
(en)
*
|
2003-05-20 |
2008-01-31 |
Jonathan Lewis |
Combination Chemotherapy Comprising Capecitabine and a Liposomal Platinum Complex
|
BRPI0410846B8
(pt)
*
|
2003-05-30 |
2021-05-25 |
Gilead Pharmasset Llc |
nucleosídeo e composição farmacêutica compreendendo o mesmo
|
US20060034943A1
(en)
*
|
2003-10-31 |
2006-02-16 |
Technology Innovations Llc |
Process for treating a biological organism
|
CN100450998C
(zh)
*
|
2003-11-11 |
2009-01-14 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
KR101226631B1
(ko)
|
2004-02-06 |
2013-01-28 |
쓰레솔드 파마슈티컬스, 인코포레이티드 |
항암 치료 방법
|
EP1732947B1
(en)
*
|
2004-03-05 |
2011-04-27 |
Vegenics Pty Ltd |
Growth factor binding constructs materials and methods
|
US20050249667A1
(en)
*
|
2004-03-24 |
2005-11-10 |
Tuszynski Jack A |
Process for treating a biological organism
|
CN102199181B
(zh)
*
|
2004-07-21 |
2014-09-17 |
吉利德制药有限责任公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
KR100578616B1
(ko)
*
|
2004-07-23 |
2006-05-10 |
한미약품 주식회사 |
D-에리트로-2,2-다이플루오로-2-데옥시-1-옥소라이보스화합물의 제조방법
|
US7858761B2
(en)
*
|
2004-07-29 |
2010-12-28 |
Hanmi Pharm. Co., Ltd |
1-α-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivatives and process for the preparation thereof
|
WO2006015346A1
(en)
*
|
2004-07-30 |
2006-02-09 |
Pharmaessentia Corp. |
STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
|
ES2769377T3
(es)
|
2004-09-14 |
2020-06-25 |
Gilead Pharmasset Llc |
Intermedios de D-ribonolactona con sustitución de 2-fluoro-2-alquilo
|
WO2006030826A1
(ja)
*
|
2004-09-17 |
2006-03-23 |
Eisai R & D Management Co., Ltd. |
医薬組成物
|
US20060089328A1
(en)
*
|
2004-10-22 |
2006-04-27 |
Edgar Schridde |
Ready-to-use gemcitabine solutions
|
US7563570B2
(en)
*
|
2004-10-29 |
2009-07-21 |
Pangaea Biotech |
Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
|
KR20070073958A
(ko)
*
|
2004-12-08 |
2007-07-10 |
시코르, 인크. |
디플루오로뉴클레오시드 및 이의 제조 방법
|
DE602005009255D1
(de)
*
|
2004-12-17 |
2008-10-02 |
Lilly Co Eli |
Amid-prodrug von gemcitabin, zusammensetzungen und verwendung damit
|
JP5475234B2
(ja)
|
2005-01-21 |
2014-04-16 |
アステックス・セラピューティクス・リミテッド |
医薬化合物
|
MX2007010316A
(es)
*
|
2005-03-04 |
2008-02-19 |
Dabur Pharma Ltd |
Intermediario de 21-desoxi, 21,21-difluoro-d-ribofuranosil nucleosidos enriquecidos en (-anomero y proceso para prepararlo.
|
TWI368621B
(en)
*
|
2005-05-02 |
2012-07-21 |
Leyoung Biotech Co Ltd |
Stereoselective synthesis of β-nucleosides
|
AU2011202539B2
(en)
*
|
2005-06-03 |
2012-07-05 |
Scinopharm Taiwan, Ltd. |
Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl sulfonate and use thereof for making a beta nucleoside
|
CN101203525B
(zh)
*
|
2005-06-03 |
2012-06-13 |
台湾神隆股份有限公司 |
制备α-端基异构体富集的2-脱氧-2,2-二氟-D-呋喃核糖基磺酸酯的方法及其制备β核苷的应用
|
WO2007011962A2
(en)
|
2005-07-18 |
2007-01-25 |
Bipar Sciences, Inc. |
Treatment of cancer
|
AT502221A1
(de)
*
|
2005-07-20 |
2007-02-15 |
Pharmacon Forschung & Beratung Gmbh |
Homogemcitabine, verfahren zu ihrer herstellung sowie deren verwendung
|
US20100105031A1
(en)
*
|
2005-08-01 |
2010-04-29 |
Esai R & D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
US9006240B2
(en)
|
2005-08-02 |
2015-04-14 |
Eisai R&D Management Co., Ltd. |
Method for assay on the effect of vascularization inhibitor
|
WO2007015257A2
(en)
*
|
2005-08-04 |
2007-02-08 |
Hetero Drugs Limited |
A process for the preparation of gemcitabine using novel intermediates
|
CN102716490A
(zh)
*
|
2005-09-01 |
2012-10-10 |
卫材R&D管理有限公司 |
药物组合物的崩解性的改善方法
|
US8193354B2
(en)
|
2005-10-28 |
2012-06-05 |
Arch Pharmalabs Limited |
Process for preparation of Gemcitabine hydrochloride
|
CN101316590B
(zh)
*
|
2005-11-07 |
2011-08-03 |
卫材R&D管理有限公司 |
血管生成抑制剂和c-kit激酶抑制剂的组合使用
|
EP1964837A4
(en)
*
|
2005-11-22 |
2010-12-22 |
Eisai R&D Man Co Ltd |
Antitumor agent against multiple myeloma
|
AU2006325622B2
(en)
*
|
2005-12-14 |
2011-02-03 |
Dong-A Pharm. Co., Ltd. |
A manufacturing process of 2',2'-difluoronucleoside and intermediate
|
WO2007117760A2
(en)
*
|
2006-02-06 |
2007-10-18 |
Dr. Reddy's Laboratories Ltd. |
Preparation of gemcitabine
|
WO2007092705A2
(en)
*
|
2006-02-07 |
2007-08-16 |
Chemagis Ltd. |
Process for preparing gemcitabine and associated intermediates
|
US20070249823A1
(en)
*
|
2006-04-20 |
2007-10-25 |
Chemagis Ltd. |
Process for preparing gemcitabine and associated intermediates
|
WO2007136103A1
(ja)
*
|
2006-05-18 |
2007-11-29 |
Eisai R & D Management Co., Ltd. |
甲状腺癌に対する抗腫瘍剤
|
US20090203693A1
(en)
*
|
2006-06-29 |
2009-08-13 |
Eisai R & D Management Co., Ltd. |
Therapeutic agent for liver fibrosis
|
US20100160442A1
(en)
*
|
2006-07-18 |
2010-06-24 |
Ossovskaya Valeria S |
Formulations for cancer treatment
|
KR100741310B1
(ko)
*
|
2006-08-01 |
2007-08-01 |
(주) 유일팜테크 |
젬시타빈의 합성에 유용한 신규한나프탈렌-2-카르복실레이트 유도체와 그의 제조방법
|
US8865737B2
(en)
*
|
2006-08-28 |
2014-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
WO2008033466A2
(en)
*
|
2006-09-14 |
2008-03-20 |
Combinatorx (Singapore) Pre. Ltd. |
Compositions and methods for treatment of viral diseases
|
JP5528806B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
JP5528807B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
PT2502938E
(pt)
|
2006-10-27 |
2015-06-05 |
Genentech Inc |
Anticorpos e imunoconjugados e suas utilizações
|
US8921340B2
(en)
|
2006-11-17 |
2014-12-30 |
Trustees Of Dartmouth College |
Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
|
EP2094651A1
(en)
*
|
2006-11-17 |
2009-09-02 |
Trustees Of Dartmouth College |
Synthesis and biological activities of new tricyclic-bis-enones (tbes)
|
WO2008064132A2
(en)
*
|
2006-11-17 |
2008-05-29 |
Trustees Of Dartmouth College |
Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
|
CA2675736A1
(en)
|
2007-01-19 |
2008-07-24 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of pancreatic cancer
|
EP2119707B1
(en)
*
|
2007-01-29 |
2015-01-14 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated-type of gastric cancer
|
US7994310B2
(en)
*
|
2007-03-23 |
2011-08-09 |
Dongwoo Syntech Co., Ltd. |
Process for preparing 2′-deoxy-2′, 2′-difluorocytidine
|
CN101024667B
(zh)
*
|
2007-03-30 |
2011-01-26 |
湖北益泰药业有限公司 |
盐酸吉西他宾的合成方法
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
US8765690B2
(en)
*
|
2007-04-05 |
2014-07-01 |
Threshold Pharmaceuticals, Inc. |
Treatment of cancer with glufosfamide in patients not receiving insulin therapy
|
US20080262215A1
(en)
*
|
2007-04-23 |
2008-10-23 |
Chemagis Ltd. |
Gemcitabine production process
|
CN100475832C
(zh)
*
|
2007-05-31 |
2009-04-08 |
南京卡文迪许生物工程技术有限公司 |
一种新颖的高立体选择性合成吉西他滨工艺及中间体
|
WO2009011924A1
(en)
*
|
2007-07-18 |
2009-01-22 |
Genelux Corporation |
Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
|
WO2009023845A2
(en)
*
|
2007-08-15 |
2009-02-19 |
The Board Of Regents Of The University Of Texas System |
Combination therapy with synthetic triterpenoids and gemcitabine
|
TWI436775B
(zh)
*
|
2007-08-24 |
2014-05-11 |
Oncotherapy Science Inc |
以抗原胜肽合併化療藥劑治療胰臟癌
|
US20090069354A1
(en)
*
|
2007-09-12 |
2009-03-12 |
Protia, Llc |
Deuterium-enriched gemcitabine
|
WO2009042064A2
(en)
|
2007-09-21 |
2009-04-02 |
Nektar Therapeutics Al, Corporation |
Oligomer-nucleoside phosphate conjugates
|
JP4253357B1
(ja)
|
2007-09-27 |
2009-04-08 |
株式会社湯山製作所 |
手撒き薬剤供給装置、薬剤の手撒き方法、及び、薬剤分包装置
|
JO2778B1
(en)
|
2007-10-16 |
2014-03-15 |
ايساي انك |
Certain vehicles, installations and methods
|
BRPI0817364A2
(pt)
*
|
2007-11-06 |
2019-09-24 |
Pharmaessentia Corp |
processo de preparação de um composto de beta-nucleosídeo e composto
|
MX2010005104A
(es)
|
2007-11-09 |
2010-08-04 |
Peregrine Pharmaceuticals Inc |
Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
|
JP5638244B2
(ja)
|
2007-11-09 |
2014-12-10 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質と抗腫瘍性白金錯体との併用
|
AU2008321382A1
(en)
*
|
2007-11-12 |
2009-05-22 |
Bipar Sciences, Inc. |
Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
|
LT2252283T
(lt)
*
|
2008-01-11 |
2019-03-25 |
Reata Pharmaceuticals, Inc. |
Sintetiniai triterpenoidai ir jų panaudojimo būdai gydant ligą
|
MX2010008187A
(es)
*
|
2008-01-29 |
2010-08-10 |
Eisai R&D Man Co Ltd |
Uso combinado de inhibidor de angiogenesis y taxano.
|
WO2009146216A2
(en)
|
2008-04-18 |
2009-12-03 |
Reata Pharmaceuticals. Inc. |
Antioxidant inflammation modulators: novel derivatives of oleanolic acid
|
ME02751B
(me)
|
2008-04-18 |
2018-01-20 |
Reata Pharmaceuticals Inc |
Antioksidansni modulatori upale: c-17 homologisani derivati oleanolinske kiseline
|
DK2276493T3
(da)
|
2008-04-18 |
2019-01-02 |
Reata Pharmaceuticals Inc |
Antioxidative inflammationsmodulatorer: oleanolsyrederivater med amino- og andre modifikationer ved c-17
|
KR101713140B1
(ko)
|
2008-04-18 |
2017-03-08 |
리타 파마슈티컬스 잉크. |
C-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
|
WO2009146218A2
(en)
|
2008-04-18 |
2009-12-03 |
Reata Pharmaceuticals, Inc. |
Compounds including an anti-inflammatory pharmacore and methods of use
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
NZ590058A
(en)
*
|
2008-06-12 |
2012-08-31 |
Scinopharm Taiwan Ltd |
Crystalline polymorphs of gemcitabine base
|
CA2731650A1
(en)
|
2008-07-22 |
2010-01-28 |
Tadashi Honda |
Monocyclic cyanoenones and methods of use thereof
|
WO2010019396A1
(en)
*
|
2008-08-13 |
2010-02-18 |
Threshold Pharmaceuticals, Inc. |
Administration of glufosfamide for the treatment of cancer
|
WO2010049947A2
(en)
*
|
2008-10-28 |
2010-05-06 |
Accrete Pharmaceutical Private Limited |
Preparation of gemcitabine and intermediates thereof
|
CN102753563A
(zh)
|
2008-12-23 |
2012-10-24 |
吉利德制药有限责任公司 |
核苷类似物
|
AU2009329867B2
(en)
|
2008-12-23 |
2015-01-29 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
NZ593647A
(en)
|
2008-12-23 |
2013-08-30 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
AU2010234562B2
(en)
*
|
2009-04-06 |
2016-05-12 |
Otsuka Pharmaceutical Co., Ltd. |
Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
|
EP2416780B1
(en)
*
|
2009-04-06 |
2017-03-08 |
Otsuka Pharmaceutical Co., Ltd. |
Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer
|
US8609631B2
(en)
|
2009-04-06 |
2013-12-17 |
Eisai Inc. |
Compositions and methods for treating cancer
|
US8324180B2
(en)
*
|
2009-04-06 |
2012-12-04 |
Eisai Inc. |
Compositions and methods for treating cancer
|
US20100273730A1
(en)
*
|
2009-04-27 |
2010-10-28 |
Innopharmax, Inc. |
Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
|
GB0907551D0
(en)
|
2009-05-01 |
2009-06-10 |
Univ Dundee |
Treatment or prophylaxis of proliferative conditions
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI598358B
(zh)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US9676797B2
(en)
|
2015-09-02 |
2017-06-13 |
Abbvie Inc. |
Anti-viral compounds
|
EP2459170A2
(en)
|
2009-07-31 |
2012-06-06 |
Astron Research Limited |
A stable composition of ready-to-use gemcitabine injection
|
US8993535B2
(en)
|
2009-09-04 |
2015-03-31 |
Merck Sharp & Dohme Corp. |
Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
|
CN102947302A
(zh)
|
2010-02-18 |
2013-02-27 |
西班牙国家癌症研究中心 |
三唑并[4,5-b]吡啶衍生物
|
ES2575160T3
(es)
|
2010-03-15 |
2016-06-24 |
The Board Of Trustees Of The University Of Illinois |
Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
BR112012024884A2
(pt)
|
2010-03-31 |
2016-10-18 |
Gilead Pharmasset Llc |
síntese estereosseletiva de ativos contendo fósforo
|
WO2011143590A1
(en)
|
2010-05-14 |
2011-11-17 |
Cornerstone Pharmaceuticals, Inc. |
Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
|
WO2011143593A1
(en)
|
2010-05-14 |
2011-11-17 |
Cornerstone Pharmaceuticals, Inc. |
Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
|
CA2802644C
(en)
|
2010-06-25 |
2017-02-21 |
Eisai R & D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
AU2011305655B2
(en)
|
2010-09-22 |
2015-11-05 |
Alios Biopharma, Inc. |
Substituted nucleotide analogs
|
WO2012069972A1
(en)
|
2010-11-19 |
2012-05-31 |
Piramal Life Sciences Limited |
A pharmaceutical combination for the treatment of breast cancer
|
ES2716158T3
(es)
|
2010-11-30 |
2019-06-10 |
Gilead Pharmasset Llc |
2'-spiro-nucleótidos para el tratamiento de hepatitis C
|
EP2655401B1
(en)
|
2010-12-20 |
2016-03-09 |
The Regents of the University of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
CN102153602B
(zh)
*
|
2011-02-24 |
2013-11-06 |
中国农业大学 |
呋喃糖基修饰的1,3,4-噻二唑衍生物及其制备方法与作为杀菌剂的应用
|
CN102153601A
(zh)
*
|
2011-02-26 |
2011-08-17 |
湖南欧亚生物有限公司 |
一种高选择性的制备盐酸吉西他滨以及其中间体的方法
|
WO2012123889A1
(en)
|
2011-03-14 |
2012-09-20 |
Piramal Healthcare Limited |
A synergistic pharmaceutical combination for the treatment of pancreatic cancer
|
AU2012236166A1
(en)
|
2011-04-01 |
2013-11-14 |
Genentech, Inc. |
Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use
|
TWI462931B
(zh)
|
2011-04-07 |
2014-12-01 |
Pharmaessentia Corp |
β-核苷的合成技術
|
JP2014515023A
(ja)
|
2011-04-13 |
2014-06-26 |
メルク・シャープ・アンド・ドーム・コーポレーション |
2’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法
|
EP2697242B1
(en)
|
2011-04-13 |
2018-10-03 |
Merck Sharp & Dohme Corp. |
2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
US9150603B2
(en)
|
2011-04-13 |
2015-10-06 |
Merck Sharp & Dohme Corp. |
2′-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases
|
WO2012144463A1
(ja)
|
2011-04-18 |
2012-10-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療剤
|
JP6038128B2
(ja)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
|
CN102453064B
(zh)
*
|
2011-06-30 |
2014-07-09 |
江苏豪森药业股份有限公司 |
制备吉西他滨盐酸盐的方法
|
EP2731433A4
(en)
|
2011-07-13 |
2014-12-31 |
Merck Sharp & Dohme |
5'-SUBSTITUTED NUCLEOSIDE ANALOGUES AND METHODS OF USE FOR THE TREATMENT OF VIRAL DISEASES
|
US9416154B2
(en)
|
2011-07-13 |
2016-08-16 |
Merck Sharp & Dohme Corp. |
5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
EP4176871A1
(en)
|
2011-10-03 |
2023-05-10 |
Canqura Oncology Ab |
Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
|
CN102417533A
(zh)
*
|
2011-10-28 |
2012-04-18 |
江苏正大清江制药有限公司 |
盐酸吉西他滨的合成方法
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
NO2755614T3
(sv)
|
2012-01-03 |
2018-03-31 |
|
|
EP2828277A1
(en)
|
2012-03-21 |
2015-01-28 |
Vertex Pharmaceuticals Incorporated |
Solid forms of a thiophosphoramidate nucleotide prodrug
|
EP2827876A4
(en)
|
2012-03-22 |
2015-10-28 |
Alios Biopharma Inc |
PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
|
EA031986B1
(ru)
|
2012-04-04 |
2019-03-29 |
Галозим, Инк. |
Способ и комбинация для лечения солидной раковой опухоли и набор, содержащий комбинацию
|
US8921419B2
(en)
|
2012-05-08 |
2014-12-30 |
Trustees Of Dartmouth College |
Triterpenoids and compositions containing the same
|
JP6165848B2
(ja)
|
2012-05-22 |
2017-07-19 |
イデニク ファーマシューティカルズ エルエルシー |
肝疾患のためのd−アミノ酸化合物
|
KR101909801B1
(ko)
|
2012-06-08 |
2018-10-18 |
에프. 호프만-라 로슈 아게 |
암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
|
MX358281B
(es)
|
2012-07-04 |
2018-08-13 |
Hoffmann La Roche |
Conjugados de antigeno-anticuerpo covalentemente enlazados.
|
EP2711008A1
(en)
|
2012-09-19 |
2014-03-26 |
Institut Univ. de Ciència i Tecnologia, S.A. |
N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
|
EP2711007A1
(en)
|
2012-09-19 |
2014-03-26 |
Institut Univ. de Ciència i Tecnologia, S.A. |
4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
|
EP2711009A1
(en)
|
2012-09-19 |
2014-03-26 |
Institut Univ. de Ciència i Tecnologia, S.A. |
Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
|
CN104936970A
(zh)
|
2012-10-08 |
2015-09-23 |
埃迪尼克斯医药公司 |
用于hcv感染的2′-氯核苷类似物
|
EP2919759A4
(en)
|
2012-11-14 |
2016-07-20 |
Ohio State Innovation Foundation |
MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES
|
KR20150098605A
(ko)
|
2012-12-21 |
2015-08-28 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
퀴놀린 유도체의 비정질 형태 및 그의 제조방법
|
US9907846B2
(en)
|
2013-04-01 |
2018-03-06 |
Mx Adjuvac Ab |
Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
|
US10517861B2
(en)
|
2013-05-14 |
2019-12-31 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
JP6476591B2
(ja)
*
|
2013-06-05 |
2019-03-06 |
セントラル硝子株式会社 |
(2R)−2−フルオロ−2−C−メチル−D−リボノ−γ−ラクトン類の製造方法
|
WO2015003747A1
(en)
*
|
2013-07-10 |
2015-01-15 |
Asteriapharma Gmbh |
Composition containing modified derivatives of a cytidine antimetabolite for the treatment of susceptible disease
|
CN105792845A
(zh)
*
|
2013-07-26 |
2016-07-20 |
施瑞修德制药公司 |
使用低氧活化的前药与紫杉烷类化合物的组合治疗胰腺癌
|
PT3650014T
(pt)
|
2013-08-27 |
2021-12-27 |
Gilead Pharmasset Llc |
Formulação combinada de dois compostos antivirais
|
KR102272773B1
(ko)
|
2013-10-29 |
2021-07-02 |
오츠카 세이야쿠 가부시키가이샤 |
2'-데옥시-2',2'-디플루오로테트라하이드로우리딘의 합성 경로
|
US10080807B2
(en)
|
2014-06-09 |
2018-09-25 |
Lipomedix Pharmaceuticals Ltd. |
Combination chemotherapy comprising a liposomal prodrug of mitomycin C
|
JP6654581B2
(ja)
|
2014-06-26 |
2020-02-26 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
抗brdu抗体および使用方法
|
TWI721954B
(zh)
|
2014-08-28 |
2021-03-21 |
日商衛材R&D企管股份有限公司 |
高純度喹啉衍生物及其生產方法
|
CN107683289B
(zh)
|
2015-01-26 |
2021-08-06 |
芝加哥大学 |
IL13Rα2结合剂和其在癌症治疗中的用途
|
WO2016123143A1
(en)
|
2015-01-26 |
2016-08-04 |
The University Of Chicago |
CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
|
US20180044368A1
(en)
*
|
2015-02-25 |
2018-02-15 |
Ligand Pharmaceuticals, Inc. |
Gemcitabine derivatives
|
SI3263106T1
(sl)
|
2015-02-25 |
2024-02-29 |
Eisai R&D Management Co., Ltd. |
Postopek zatiranja grenkobe derivata kinolina
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
CA2988707C
(en)
|
2015-06-16 |
2023-10-10 |
Eisai R&D Management Co., Ltd. |
Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
|
US10660912B2
(en)
*
|
2015-10-05 |
2020-05-26 |
NuCana plc |
Combination therapy for cancer
|
WO2017098252A1
(en)
|
2015-12-11 |
2017-06-15 |
Nucana Biomed Limited |
Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
|
WO2017157825A1
(en)
|
2016-03-15 |
2017-09-21 |
F. Hoffmann-La Roche Ag |
Combinations of lsd1 inhibitors for use in the treatment of solid tumors
|
US11246905B2
(en)
|
2016-08-15 |
2022-02-15 |
President And Fellows Of Harvard College |
Treating infections using IdsD from Proteus mirabilis
|
AU2017361541A1
(en)
|
2016-11-21 |
2019-07-11 |
Bexion Pharmaceuticals, Inc. |
A combination therapy including SapC-DOPS for the treatment of pancreatic cancer
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
CA3049435A1
(en)
|
2017-01-09 |
2018-07-12 |
Scott Grindrod |
Selective histone deacetylase inhibitors for the treatment of human disease
|
MA49289A
(fr)
|
2017-04-03 |
2020-02-12 |
Hoffmann La Roche |
Anticorps se liant à steap-1
|
BR112019022470A2
(pt)
|
2017-04-26 |
2020-05-12 |
I. Kalman Thomas |
Composto, composição, e, método para tratamento de um indivíduo com câncer.
|
MX2020001451A
(es)
|
2017-08-07 |
2020-08-06 |
Amgen Inc |
Tratamiento de cancer de mama triple negativo o cancer colorrectal con metastasis hepaticas con un anticuerpo anti-pd-l1 y un virus oncolitico.
|
CN111565744A
(zh)
|
2017-09-18 |
2020-08-21 |
加利福尼亚大学董事会 |
紧密连接蛋白6抗体和治疗癌症的方法
|
US10435429B2
(en)
|
2017-10-03 |
2019-10-08 |
Nucorion Pharmaceuticals, Inc. |
5-fluorouridine monophosphate cyclic triester compounds
|
CN112004537A
(zh)
|
2018-01-09 |
2020-11-27 |
穿梭药业公司 |
用于治疗人疾病的选择性组蛋白去乙酰化酶抑制剂
|
US11427550B2
(en)
|
2018-01-19 |
2022-08-30 |
Nucorion Pharmaceuticals, Inc. |
5-fluorouracil compounds
|
BR112020015745A2
(pt)
|
2018-02-02 |
2020-12-08 |
Maverix Oncology, Inc. |
Conjugados de fármacos de moléculas pequenas de monofosfato de gemcitabina
|
TW202002952A
(zh)
|
2018-03-15 |
2020-01-16 |
美商艾伯維有限公司 |
用於治療胰臟癌之abbv-621與抗癌劑之組合
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
WO2020044252A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Dosage regimes for anti-m-csf antibodies and uses thereof
|
EP3669890A1
(en)
|
2018-12-18 |
2020-06-24 |
Croda International PLC |
Filamentous nanoparticles having vaccine adjuvant effect
|
US20220087975A1
(en)
|
2019-01-11 |
2022-03-24 |
Lipomedix Pharmaceuticals Ltd. |
Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
|
CN114174340A
(zh)
|
2019-03-20 |
2022-03-11 |
加利福尼亚大学董事会 |
密封蛋白-6抗体和药物缀合物
|
US20220177583A1
(en)
|
2019-03-20 |
2022-06-09 |
The Regents Of The University Of California |
Claudin-6 bispecific antibodies
|
JP2022530241A
(ja)
|
2019-04-30 |
2022-06-28 |
インスチトゥート デ メディシーナ モリクラール ジョアン ロボ アントゥネス |
Cdk阻害剤と組み合わせたrank経路阻害剤
|
AU2020303986A1
(en)
|
2019-06-24 |
2021-12-09 |
Amgen Inc. |
Inhibition of SIRP-gamma for cancer treatment
|
WO2021209563A1
(en)
|
2020-04-16 |
2021-10-21 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|
JP2023523415A
(ja)
|
2020-04-21 |
2023-06-05 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
ヌクレオチドプロドラッグ化合物
|